期刊文献+

北京地区37例流感患者的病毒遗传变异及耐药突变分析 被引量:5

Genetic variation and drug resistance mutation of influenza virus during 2013-2014 in Beijing, China: a report of 37 cases
下载PDF
导出
摘要 目的分析2013-2014年度北京地区A型H1N1、H3N2和B型流感病毒神经氨酸酶(NA)基因的遗传变异情况,以及流感病毒对金刚烷胺类和NA抑制剂类(NAIs)抗病毒药物的耐药变异情况。方法从37例流感病毒感染患者的鼻/咽拭子样本中提取RNA,采用荧光定量PCR检测流感病毒的基因型/亚型;反转录PCR方法扩增A型流感病毒的NA和基质蛋白M2(M2)基因片段及B型流感病毒的NA和血凝素(HA)基因片段,直接DNA测序。采用Mega软件构建系统进化树分析病毒的演变情况,Vector NTI软件分析耐药变异情况。结果 37例患者中共检出A型流感病毒29例,其中H1N1 23例,H3N2 6例;B型流感病毒8例。所有A型流感病毒均发生M2基因S31N金刚烷胺类药物耐药位点变异。A型和B型流感病毒均未发现NAIs耐药位点变异。系统进化分析显示,B型流感病毒有5例样品NA基因和HA基因分型不一致,NA基因均为B-Victoria系,而HA基因为B-Yamagata系。结论北京地区人群A型流感病毒均对金刚烷胺类药物耐药,但A型和B型病毒均未检测出NAIs耐药变异。B型流感病毒流行株中存在B-Yamagata系和B-Victoria系重组病毒株。 Objective To evaluate the evolutionary characteristics of H1N1 and H3N2 influenza A and B viruses, and investigate the drug-resistant mutation of influenza viruses to amantadine and neuraminidase inhibitors(NAIs) during 2013-2014 episode in Beijing. Methods RNA was extracted from pharyngeal or nasal swab samples from 37 influenza virus-infected patients and viral genotype/subgenotype were analyzed by real-time reverse-transcription polymerase chain reaction. All influenza A viruses were further directly sequenced for NA and M2 matrix protein(M2) genes, and all influenza B viruses were further sequenced for NA and hemagglutinin(HA) genes. The drug-resistant mutations and genetic evolution were analyzed by Vector NTI software and phylogenetic trees were plotted using Mega software. Results Influenza A viruses were identified in 29 patients, including 23 with H1N1 and 6 with H3N2 viruses. Influenza B viruses were identified in 8 patients. M2 gene of all 29 patients with influenza A virus infection were detected with S31 N amantadine-resistant mutation. NAIs-resistant mutations were not detected in all 37 patients with influenza A and B virus infection. Phylogenetic analysis showed that HA genes from 5 influenza B virus strains were identified as the B-Yamagata lineage, while NA genes from the corresponding strains were identified as B-Victoria lineage. Conclusions Among Beijing Influenza B virus strains reassortants derived from B-Yamagata lineage and B-Victoria lineage were found.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2016年第2期108-113,共6页 Medical Journal of Chinese People's Liberation Army
基金 北京市科委科技计划项目(D131100005313016) 新发突发传染病研究北京市重点实验室资助项目(2014XFTF04) 全军医学科技"十二五"科研项目重点课题(BWS11J048)~~
关键词 流感病毒 金刚烷胺 神经氨酸酶抑制剂 抗药性 突变 influenza virus human amantadine neuraminidase inhibitors drug resistance mutation
  • 相关文献

参考文献30

  • 1Fouchier RA, Munster V, Wallensten A, et al. Characterization ofa novel influenza A virus hemagglutinin subtype (H16) obtainedfrom black-headed gulls[J]. J Virol, 2005, 79(5): 2814-2822.
  • 2Kanegae Y, Sugita S, Endo A, et al. Evolutionary pattern of thehemagglutinin gene of influenza B viruses isolated in Japan:cocirculating lineages in the same epidemic season[J]. J Virol,1990, 64(6): 2860-2865.
  • 3Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of twodistinct evolutionary lineages of influenza type B virus since1983[J]. Virology, 1990, 175(1): 59-68.
  • 4Shaw MW, Xu X, Li Y, et al. Reappearance and global spreadof variants of influenza B/Victoria/2/87 lineage viruses in the2000-2001 and 2001-2002 seasons[J]. Virology, 2002, 303(1):1-8.
  • 5Klimov AI, Garten R, Russell C, et al. WHO recommendationsfor the viruses to be used in the 2012 Southern HemisphereInfluenza Vaccine: epidemiology, antigenic and geneticcharacteristics of influenza A(H1N1)pdm09, A(H3N2) and Binfluenza viruses collected from February to September 2011[J].Vaccine, 2012, 30(45): 6461-6471.
  • 6Loving CL, Lager KM, Vincent AL, et al. Efficacy in pigs ofinactivated and live attenuated influenza virus vaccines againstinfection and transmission of an emerging H3N2 similar to the2011-2012 H3N2v[J]. J Virol, 2013, 87(17): 9895-9903.
  • 7Ma C, Soto CS, Ohigashi Y, et al. Identification of the pore-liningresidues of the BM2 ion channel protein of influenza B virus[J].J Biol Chem, 2008, 283(23): 15921-15931.
  • 8Meijer A, Rebelo-de-Andrade H, Correia V, et al. Globalupdate on the susceptibility of human influenza viruses toneuraminidase inhibitors, 2012-2013[J]. Antivir Res, 2014, 110:31-41.
  • 9Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and itspotential for use in the event of an influenza pandemic[J]. JAntimicrob Chemother, 2005, 55(Suppl 1): i5-i21.
  • 10Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivirtreatment of influenza in children[J]. Pediatr Infect Dis J, 2001,20(2): 127-133.

二级参考文献40

共引文献12

同被引文献54

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部